JPS6363620A - Mixture of three kinds of living bacteria - Google Patents
Mixture of three kinds of living bacteriaInfo
- Publication number
- JPS6363620A JPS6363620A JP61206018A JP20601886A JPS6363620A JP S6363620 A JPS6363620 A JP S6363620A JP 61206018 A JP61206018 A JP 61206018A JP 20601886 A JP20601886 A JP 20601886A JP S6363620 A JPS6363620 A JP S6363620A
- Authority
- JP
- Japan
- Prior art keywords
- bacteria
- butyric acid
- mixture
- acid bacteria
- saccharifying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 24
- 235000014655 lactic acid Nutrition 0.000 claims description 12
- 239000004310 lactic acid Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 241000193171 Clostridium butyricum Species 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 244000063299 Bacillus subtilis Species 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 229920002261 Corn starch Polymers 0.000 abstract description 2
- 241000194032 Enterococcus faecalis Species 0.000 abstract description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 2
- 229930006000 Sucrose Natural products 0.000 abstract description 2
- 239000008120 corn starch Substances 0.000 abstract description 2
- 229920001592 potato starch Polymers 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000005720 sucrose Substances 0.000 abstract description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 230000028070 sporulation Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 description 12
- 241000194017 Streptococcus Species 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
Landscapes
- Fodder In General (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】 本発明は、活性生菌類の共生混合物に関する。[Detailed description of the invention] The present invention relates to a symbiotic mixture of active living fungi.
更だ詳しく述べれば、ヒトもしくは動物にとって有益な
る乳酸菌、糖化菌および酪酸菌を有効成分とし、これに
適宜賦形剤を配合して成る３種菌共生混合物に関する。More specifically, the present invention relates to a symbiotic mixture of three types of bacteria, which contains lactic acid bacteria, saccharifying bacteria, and butyric acid bacteria that are beneficial to humans or animals as active ingredients, and contains appropriate excipients.
活性生菌類は厄用微生物工業の各分野において重要な役
割を演じており、これら活性生菌類を２種もしくは２種
以上混合（共存）させた状態で利用（経口投与）する場
合ては生体内において微生物の共生現象すなわち共存す
る微生物が互いに有利な影響を与え合うという効果が期
待されることがあるが、この共生現象を積他的に応用し
た製品は少ない。Active living fungi play an important role in various fields of harmful microorganism industry, and when two or more of these active living fungi are used in a mixed (coexistence) state (oral administration) Although it is sometimes expected that there will be a symbiotic phenomenon of microorganisms, that is, an effect in which coexisting microorganisms exert mutually advantageous effects on each other, there are few products that have applied this symbiotic phenomenon in an altruistic way.
本発明者は、共生現象を示す活性生菌共生混合物の応用
に早（から着目し検討を加えた結果、乳酸菌、糖化菌お
よび酪酸菌を有効成分とする３＄ｉ菌共生混合物を創製
し、医薬品、健康食品、飼料などの分野における製品主
原料への応用に成功した。The present inventor has focused on the application of a symbiotic mixture of active living bacteria that exhibits a symbiotic phenomenon, and as a result of further investigation, has created a 3$i bacterial symbiotic mixture containing lactic acid bacteria, saccharifying bacteria, and butyric acid bacteria as active ingredients, It has been successfully applied as a main raw material for products in fields such as pharmaceuticals, health foods, and feed.
３種菌共生混合物の各成分間における共生現象に基ずく
菌数の発育増加傾向に関しては以下の通りである。まず
、糖化菌と乳酸菌との共生てついて述べると、乳酸菌単
独培養の場合と糖化菌培養Ｆ液を添加した培地で乳酸菌
を培養した場合とを比較した時、乳酸菌の菌数において
前者の場合に比較して後者の場合には約５０〜１００倍
の増加傾向が認められる。これは楯化菌が発育時に産生
ずるプロテアーゼおよびアミラーゼが周囲（培地あるい
は生体内）の蛋白質および炭水化物をそれぞれ分解して
乳ｒＲ菌増殖に必要なアミノ酸（グルタミン酸、アスパ
ラギン酸など）およびブドウ糖を供給し、乳酸菌の発育
増殖を促進させることによるものと考えられる。更に、
乳１ズ菌と酪酸菌との共生について述べると、それぞれ
の菌を単独培養した場合と両ｊを混合培養した場合とを
比較した時、酪酸菌の菌数においては混合培養の方が約
１０イさ前後、乳酸菌の菌数についても混合培養の方が
数倍の増加傾向が詔められる。これは混合培養によって
それぞれの菌が互いに相手にとって有利な増殖促進因子
を産生していることによるものと考えられる。The growth tendency of the number of bacteria based on the symbiotic phenomenon among the components of the three-species bacterial symbiotic mixture is as follows. First, regarding the symbiosis between saccharifying bacteria and lactic acid bacteria, when we compare the case where lactic acid bacteria are cultured alone and the case where lactic acid bacteria are cultured in a medium supplemented with saccharifying bacteria culture solution F, the number of lactic acid bacteria is lower in the former case. In comparison, in the latter case, an increasing tendency of about 50 to 100 times is observed. This is because protease and amylase, which are produced by shield bacteria during growth, decompose surrounding proteins and carbohydrates (in the medium or in the body), respectively, and supply amino acids (glutamic acid, aspartic acid, etc.) and glucose necessary for the growth of milk rR bacteria. This is thought to be due to promoting the growth and proliferation of lactic acid bacteria. Furthermore,
Regarding the symbiosis between Lactobacillus lactis and Butyric acid bacteria, when comparing the case where each bacteria is cultured alone and the case where both are cultured together, the number of butyric acid bacteria is higher in the mixed culture by about 10. The numbers of lactic acid bacteria tend to increase several times more in the mixed culture before and after cultivation. This is thought to be due to the fact that, through mixed culture, each bacterium produces growth-promoting factors that are advantageous to the other.
本発明に適用し得る菌は一乳酸菌としてはストレプトコ
ッ力スフヱカーリｘ （５ｔｒｅｐｔｏｃｏｃｃｕｓｆ
ａｅｃａｌｉａ） ＊ストレブトコッ力スラクティス（
Ｓｔｒｅｐｔｏｃｏｃｃｕｓ １ａｃｔｉｓ）、ストレ
プトコッカス７エシウム（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ
ｆａｅｃｉｕｒｎ）の他ラクトバチルス（Ｌａｃｔｏ
ｂａｃｉｌｌｕｓ） 漠の各画などが、糖化菌としては
バチルスメセンテリカス（１３ａｃ１１１ｕ８ｍｅｓｅ
ｎｔｅｒｉｃｕｓ） 、バチルスズプチルス（Ｂａｃｉ
ｌｌｕｓｓｕｂＬｉｌｉｓ） 、バチルスナツト−（Ｂ
ａｃｉｌｌｕｓ ｎａｔｔｏ）などが、また酪酸菌とし
てはクロストリジウムブチリカム（Ｃｌｏｓｔｒｉｄｉ
ｕｍ ｂｕｔｙｒｉｃｕｍ） 、クロストリジウムアセ
トブチリカム（Ｃｌｏｓｔｒｉｄｉｕｍ ａｃｅｔｏｂ
ｕｔｙｌｉｃｕｍ）などがあげられる。なお、賦形物質
としては、バレイショテンブン、トウモロコシデンプン
、乳１゜白糖もしくはこれらの混合物が適当である。Bacteria that can be applied to the present invention include Streptococcus facari x (5 treptococcus f.
aecalia) *Streptococcus slactis (
Streptococcus 1actis), Streptococcus 7.
faeciurn) as well as Lactobacillus (Lacto
Bacillus mesentericus (13ac111u8mese) is a saccharifying bacterium.
ntericus), Bacillus subtilis (Bacillus
llussubLilis), Bacillus nut (B
acillus natto), and butyric acid bacteria include Clostridium butyricum (Clostridium butyricum).
um butyricum), Clostridium acetob
utilicum). Suitable excipients include potato starch, corn starch, milk 1° sucrose, or a mixture thereof.
３種の活性生菌の１合割合については、乳酸菌１部に対
し糖化菌および酪酸菌をそれぞれ１部ないし８部程度の
割合にて混合できる。実験データによれば乳酸菌１部π
対し″Ｃ塘化菌４．５〜５部。Regarding the ratio of the three types of active living bacteria, saccharifying bacteria and butyric acid bacteria can be mixed at a ratio of about 1 to 8 parts each to 1 part of lactic acid bacteria. According to experimental data, 1 part of lactic acid bacteria π
4.5 to 5 parts of C.
酪酸菌５．０〜５．５部の混合割合の場合が１数増加傾
向において効率的である。また、糖化菌および酪酸菌に
ついては芽胞を形成させてから使用すると耐熱性、耐乾
性、耐薬品性が増強される。A mixing ratio of 5.0 to 5.5 parts of butyric acid bacteria is efficient in increasing the number by one. Furthermore, if saccharifying bacteria and butyric acid bacteria are used after forming spores, their heat resistance, dryness resistance, and chemical resistance will be enhanced.
実施例
本発明品を整腸剤（医薬品）へ応用する混合について述
べる。EXAMPLE A description will be given of the application of the product of the present invention to an intestinal regulating agent (medicine).
（イ）使用した活性生菌のＭ種
乳酸菌としてストレプトコッカスフェカーリス（５ｔｒ
ｅｐｔｏｃｏｃｃｕｓ ｆａｅｃａｌｌｓ Ｔｌ−ＩＬ
Ｏ）微工研菌寄第８９３６号
糖化菌としてバチルスメセンテリカス
（１３ａｃｌｌｌｕｓ ｒｎｅａｅｎｔｅｒｉｃｕａ
Ｔｏ−Ａ）微工研菌寄第８９３４号
酪酸菌としてクロストリジウムブチリカム（Ｃｌｏｓｔ
ｒｉｄｉｕｍ ｂｕｔｙｒｉｃｕｍ Ｔｏ−Ａ）微工研
菌寄第８９３５号
仲）各活性生菌および賦形剤の混合割合乳酸菌原末
１部
塘化菌（芽胞）原末 ５部
酪酸菌（芽胞）原末 ５部
乳 塘 ４０部
バレイシラデンプン ４９部
ｅ→ 上記のごとく製造した３種菌共生混合物を整腸剤
として使用した。この整腸剤をヒトもしくは動物に経口
投与した際の腸内菌叢への薬理作用は以下の通りである
。(b) Streptococcus faecalis (5tr
eptococcus faecalls Tl-IL
O) Bacillus mesentericus (13acllus rneaentericua) as a saccharifying bacterium
To-A) Microtechnical Research Institute No. 8934 Clostridium butyricum (Clostridium butyricum) is a butyric acid bacterium.
ridium butyricum To-A) Microtechnical Research Institute No. 8935 Medium) Mixing ratio of each active live bacteria and excipients Lactic acid bacteria bulk powder
1 part Bacillus acidophilus (spore) bulk powder 5 parts Butyric acid bacteria (spore) bulk powder 5 parts Milk Tong 40 parts Barley silla starch 49 parts e→ The symbiotic mixture of three types of bacteria produced as described above was used as an intestinal regulator. The pharmacological effects on intestinal flora when this intestinal regulating agent is orally administered to humans or animals are as follows.
（投与例１）
ラッ）Ｋ整、腸剤を投与した場合の腸内菌叢の変化を、
投与群と対照群に分けて見たところ、投与群においてビ
フィズス菌の増加と大腸菌の減少が顕著に８１認された
。(Administration Example 1) Changes in intestinal flora when administering intestinal preparations
When divided into the administration group and the control group, a significant increase in Bifidobacterium and decrease in Escherichia coli was observed in the administration group.
（投与例２）
ラットに整腸剤を投与し腸管内ｐＨの変動を投与群と対
照群に分けて見たところ、投与群において腸管内ｐＨが
有意に低下した。これてより整腸剤が有害菌の発育を抑
制することが考えられる。(Administration Example 2) When an intestinal regulating agent was administered to rats and the changes in intestinal pH were observed by dividing the rats into an administration group and a control group, the intestinal pH significantly decreased in the administration group. This suggests that intestinal regulators suppress the growth of harmful bacteria.
（投与例３）
人工乳栄養光と整腸剤を約２週間投与して糞望中におけ
るビフィズス菌の消長を見たところ、ビフィズス菌の有
意な増加が認められたわ（投与例４）
急性腸炎韮びに習慣性便秘の症例に整、）剤１日量３ｇ
を１日〜７日間投与したところ、有効な成績を得るとと
もに、抗生物質投与時：（本則を併用することにより菌
交代症の発生防止が推定された。(Administration Example 3) After administering artificial milk nutrition light and an intestinal regulator for about two weeks and observing the change in bifidobacteria in the feces, a significant increase in bifidobacteria was observed (Administration Example 4) Acute Enteritis Dwarf 3g per day for cases of habitual constipation.
When administered for 1 to 7 days, effective results were obtained, and when antibiotics were administered, it was estimated that the use of the main rule could prevent the occurrence of bacterial replacement.
上述のごとく１本発明に係る３慄菌共生混合物を主原料
として医薬品、健康食品、飼料等に応用する時、経口投
与後体内特シで腸管内において各活性生菌が互いに共生
現象を発現し、腸内ＭＭＵの維持１回復にとって良好な
る使用効果が期待される。As mentioned above, when the symbiotic mixture of three fungal bacteria according to the present invention is used as a main raw material in medicines, health foods, feeds, etc., each active bacteria exhibits a symbiotic phenomenon with each other in the intestinal tract after oral administration. , it is expected to have good effects on the maintenance and recovery of intestinal MMU.
Claims (1)
び酪酸菌を有効成分とし、これに適宜賦形剤を配合して
成る３種菌共生混合物。A symbiotic mixture of three types of bacteria, which contains lactic acid bacteria, saccharifying bacteria, and butyric acid bacteria as active ingredients that are beneficial to humans or animals, and contains appropriate excipients.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61206018A JPH0774158B2 (en) | 1986-09-03 | 1986-09-03 | 3 species symbiotic mixture |
| US07/616,820 US5143845A (en) | 1986-09-03 | 1990-11-16 | Mixture of saccarifying lactic acid producing and butyric acid producing bacteria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61206018A JPH0774158B2 (en) | 1986-09-03 | 1986-09-03 | 3 species symbiotic mixture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6363620A true JPS6363620A (en) | 1988-03-22 |
| JPH0774158B2 JPH0774158B2 (en) | 1995-08-09 |
Family
ID=16516540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61206018A Expired - Lifetime JPH0774158B2 (en) | 1986-09-03 | 1986-09-03 | 3 species symbiotic mixture |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0774158B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0367552A (en) * | 1989-05-24 | 1991-03-22 | Toyo Jozo Co Ltd | Stable spore-forming variable cell drug, production thereof and pellet |
| EP0555618A3 (en) * | 1992-02-10 | 1994-06-22 | Vesely Renata Maria Cavaliere | Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
| KR20010008211A (en) * | 2000-11-15 | 2001-02-05 | 박준봉 | Functional fermented feed using microorganism producing organic acid and photosynthetic microorganism |
| CN1070056C (en) * | 1991-12-11 | 2001-08-29 | 日本化药株式会社 | Method to accelerating growth of animal and powdered composite of microbe cells contraining killed fusiform bacillus of bacteria |
| JP2016193894A (en) * | 2015-04-01 | 2016-11-17 | 京都薬品工業株式会社 | Viable cell-containing preparation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6163618A (en) * | 1984-09-03 | 1986-04-01 | Akira Yamauchi | Cathartic |
-
1986
- 1986-09-03 JP JP61206018A patent/JPH0774158B2/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6163618A (en) * | 1984-09-03 | 1986-04-01 | Akira Yamauchi | Cathartic |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0367552A (en) * | 1989-05-24 | 1991-03-22 | Toyo Jozo Co Ltd | Stable spore-forming variable cell drug, production thereof and pellet |
| CN1070056C (en) * | 1991-12-11 | 2001-08-29 | 日本化药株式会社 | Method to accelerating growth of animal and powdered composite of microbe cells contraining killed fusiform bacillus of bacteria |
| EP0555618A3 (en) * | 1992-02-10 | 1994-06-22 | Vesely Renata Maria Cavaliere | Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
| KR20010008211A (en) * | 2000-11-15 | 2001-02-05 | 박준봉 | Functional fermented feed using microorganism producing organic acid and photosynthetic microorganism |
| JP2016193894A (en) * | 2015-04-01 | 2016-11-17 | 京都薬品工業株式会社 | Viable cell-containing preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0774158B2 (en) | 1995-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200069749A1 (en) | Lactobacillus-based ecoli inhibition | |
| DE69839351T2 (en) | USE OF BACTERIA WITH ARGININ DEIMINASE ACTIVITY FOR THE INDUCTION OF APOPTOSIS AND / OR FOR INHIBITING AN INFLAMMATORY RESPONSE, AND THESE PHARMACEUTICAL OR DIETETIC COMPOSITIONS CONTAINING THEREOF | |
| EP0416892B2 (en) | Agents for the prevention and treatment of diarrhoea | |
| Meurman et al. | Recovery of Lactobacillus strain GG (ATCC 53103) from saliva of healthy volunteers after consumption of yoghurt prepared with the bacterium | |
| US20110117068A1 (en) | Probiotic microorganisms for the reduction of manure odor | |
| US3369969A (en) | Colibacilli containing medicament and a method of preparing same | |
| JP2002523372A (en) | Symbiotic lactic acid producing bacteria and uses thereof | |
| CN108366582A (en) | Feed addictive composition | |
| CN1272791A (en) | Pharmaceutical preparation comprising lactobacillus casei phamnosus | |
| EP3031464B1 (en) | Preventive or therapeutic agent for ruminant animal mastitis | |
| US5143845A (en) | Mixture of saccarifying lactic acid producing and butyric acid producing bacteria | |
| JPH0656680A (en) | Nutritional and/or pharmaceutical composi- tion containing freeze-dried lactic acid bacterium and preparation and use thereof | |
| JPH05502873A (en) | Pharmaceutical formulations for controlling pathogenic intestinal bacteria | |
| WO1993014187A1 (en) | A bacterial strain of the species bacillus coagulans: its use as a probiotic agent | |
| JP3648233B2 (en) | Feed composition | |
| EP3704958A1 (en) | Muscle-building composition | |
| WO1998042194A1 (en) | Stabilized solid bacteria compositions | |
| JP7072151B2 (en) | Gut microbiota improver | |
| JPS6363620A (en) | Mixture of three kinds of living bacteria | |
| JP6675703B1 (en) | Lactic acid bacteria, natural immunity activators derived from the lactic acid bacteria, infectious disease preventive / therapeutic agents, and food and drink | |
| KR101215422B1 (en) | Pediococcus acidilactici WRL-1 and use of the same | |
| Zuo et al. | Separation of growth-stimulating peptides for Bifidobacterium from soybean conglycinin | |
| WO2020189228A1 (en) | Enhancer of beneficial intestinal bacteria growth and organic acid production | |
| KR890004806B1 (en) | Mixture of three kinds of living bacteria | |
| DK200500255U3 (en) | Probiotic, broad-spectrum nutritional formulation in powder, liquid, paste or gas form |